ADIL - エ―ダイヤル・ファ―マシュ―ティカルズ （Adial Pharmaceuticals Inc）

Adial Pharmaceuticals Inc''s (NASDAQ: ADIL ) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve. At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not … Full story available on Benzinga.com

PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 significantly reduced pain compared to both placebo and acetaminophen

Adial Pharmaceuticals, Inc. was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 335,900…

Adial Pharmaceuticals (ADIL) appoints Cary J. Claiborne as President and CEO. Mr

Kevin Schuyler appointed Chairman of Adial’s Board

Adial Pharmaceuticals Inc''s (NASDAQ: ADIL ) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve. At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not … Full story available on Benzinga.com

PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 significantly reduced pain compared to both placebo and acetaminophen

Adial Pharmaceuticals, Inc. was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 335,900…

Adial Pharmaceuticals (ADIL) appoints Cary J. Claiborne as President and CEO. Mr

Kevin Schuyler appointed Chairman of Adial’s Board

CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on developing novel molecules targeting the adenosine receptors for the treatment of major unmet medical needs, has entered into a research collaboration with the Medical College of Wisconsin , a leading medical school, and Dr. John Auchampach, PhD , Professor and Vice Chair of the Department of Pharmacology and Toxicology. The goal of the collaboration is to further evaluate the Company’s proprietary adenosine analogs as potential treatments for diabetes and non-alcoholic steatohepatitis (NASH). NASH is the most severe form of non-alcoholic fatty liver disease involving liver inflammation (hepatitis) that can lead to life-threatening cardiovascular co-morbidities.

Adial Pharmaceuticals press release (ADIL): Q1 GAAP EPS of -$0.13 beats by $0.04.As of March 31, 2022, cash and cash equivalents were $12.7 million as compared to $6.1 million as…

Adial Pharmaceuticals press release (ADIL): Q1 GAAP EPS of -$0.13 beats by $0.04.As of March 31, 2022, cash and cash equivalents were $12.7M vs. $6.1M as of Dec

Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL , ADILW)) ("Adial" or the "Company"), today announced that Purnovate, Inc., an Adial company focused on developing adenosine analogs for the treatment of major unmet medical needs, has entered into a research collaboration agreement with the University of California San Diego (UC San Diego), a leading education and research university, and Dr. Peter Ernst, DVM, PhD , Professor of Pathology and an expert in the fields of immunology, inflammation and infectious disease, to further evaluate the Company''s proprietary adenosine analogs as a potential treatment for inflammatory diseases, including inflammatory bowel disease (IBD) and infectious diseases where a large immune response (i.e., cytokine storm) plays a significant role. Under the collaboration agreement, Dr. Ernst and his team will initially test Purnovate''s adenosine compounds in non-clinical models of IBD with the goal of further validating the potential of Purnovate''s compounds as a treatment for IBD.